Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
Details of the poster display and discussion are as follows:
Poster Title: Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.
Abstract Number: 3010
Poster Display: 8:00 AM –
Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms and its modular Synthemer scaffold to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC adenocarcinoma, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Source: Mersana Therapeutics, Inc.